Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.8K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.8K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

2.1K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

2.9K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.9K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

2.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
2.1K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

641
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
641

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

C-Type Natriuretic Peptide and Cardiovascular-Renal Protection in Sepsis.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

From Palpitations to Prevention: Timely Recognition of Biventricular ACM Preventing Sudden Cardiac Death.

Case reports in cardiology·2026
Same author

The Concise Guide to PHARMACOLOGY 2025/26: Catalytic receptors.

British journal of pharmacology·2025
Same author

Effects of physiological doses of atrial natriuretic peptide on lipolysis, ketogenesis, and glucose metabolism in men.

American journal of physiology. Endocrinology and metabolism·2025
Same author

C-Type Natriuretic Peptide: Protecting the Aorta.

Arteriosclerosis, thrombosis, and vascular biology·2025
Same author

Significance of common genetic variants associated with non-ischaemic cardiomyopathy in the general population.

European journal of heart failure·2025

相关实验视频

Updated: May 6, 2026

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

8.4K

在实验性心力衰竭中最大化 natriuretic 系统:皮下大脑 natriuretic 和急性血管酶抑制.

Horng H Chen1, John G Lainchbury, Gail J Harty

  • 1Cardiorenal Research Laboratory, Division of Cardiovascular Diseases and Department of Physiology, Mayo Clinic and Foundation, Rochester, Minn 55905, USA. chen.horng@mayo.edu

Circulation
|February 28, 2002
PubMed
概括

急性血管胺酶抑制剂 (VPI) 的使用在实验性充血性心力衰竭 (CHF) 中增强了脑内尿性 (BNP) 的作用. 将VPI与BNP结合起来,提供了一种新的治疗策略,以增强CHF患者的心脏和脏功能.

更多相关视频

Isolation of Atrial Myocytes from Adult Mice
08:34

Isolation of Atrial Myocytes from Adult Mice

Published on: July 25, 2019

11.7K
Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

1.4K

相关实验视频

Last Updated: May 6, 2026

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

8.4K
Isolation of Atrial Myocytes from Adult Mice
08:34

Isolation of Atrial Myocytes from Adult Mice

Published on: July 25, 2019

11.7K
Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

1.4K

科学领域:

  • 心血管研究研究心血管研究
  • 药理学 药理学是指药理学的学科.
  • 腎臟病學 (nephrology) 是一種醫學專業.

背景情况:

  • 充血性心力衰竭 (CHF) 的特点是心脏 natriuretic (NP) 的升高,具有有益的心脏和鼻性质.
  • 慢性皮下 (SQ) 大脑 natriuretic (BNP) 管理改善心脏功能在实验性CHF.
  • 血管酶抑制剂 (VPIs) 同时抑制中性内酶 (NEP) 和ACE.

研究的目的:

  • 调查急性VPI给药是否增强SQ BNP在实验性CHF中的心脏脏作用.
  • 评估VPI和BNP对心脏和脏和幽默反应的综合影响.

主要方法:

  • 研究了经过麻醉的狗,其心室节奏诱导的CHF被研究.
  • 这些组仅接受急性VPI,低剂量SQ BNP,高剂量SQ BNP,或VPI加低剂量SQ BNP.
  • 测量了心脏和幽默的参数.

主要成果:

  • 与VPI或低剂量BNP单独相比,VPI加上低剂量SQ BNP显著增加了血BNP水平.
  • 联合VPI和BNP的使用导致尿路BNP和分泌量最高.
  • 组合疗法导致了最大的膜过率,心脏输出率的增加和心脏填充压力的降低.

结论:

  • 急性VPI的使用可增强SQ BNP在实验性CHF中的心脏和脏效应.
  • 将蛋白质疗法与BNP和血管抑制相结合,为心血管衰竭治疗提供了一种新的策略.
  • 这种方法最大限度地提高了 natriuretic 系统在治疗CHF 的治疗效益.